Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Oxaliplatin, Capecitabine, and Radiation Therapy in Patients Undergoing Surgery for Stage II, III, IV Esophageal Cancer

ClinicalTrials.gov ID: NCT00470184

Public ClinicalTrials.gov record NCT00470184. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 9:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase II Study of Capecitabine in Combination With Oxaliplatin and Radiotherapy for Esophageal and Gastroesophageal Junction Cancer

Study identification

NCT ID
NCT00470184
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Roswell Park Cancer Institute
Other
Enrollment
41 participants

Conditions and interventions

Interventions

  • capecitabine Drug
  • oxaliplatin Drug
  • gene expression analysis Genetic
  • microarray analysis Genetic
  • reverse transcriptase-polymerase chain reaction Genetic
  • adjuvant therapy Procedure
  • biopsy Procedure
  • conventional surgery Procedure
  • neoadjuvant therapy Procedure
  • quality-of-life assessment Procedure
  • radiation therapy Radiation

Drug · Genetic · Procedure + 1 more

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2006
Primary completion
Sep 30, 2012
Completion
Not listed
Last update posted
Nov 24, 2013

Started 2006

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Roswell Park Cancer Institute Buffalo New York 14263-0001

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00470184, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 24, 2013 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00470184 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →